University of Milan

Luspatercept met the primary endpoints in its first two Phase III tests – in transfusion-dependent beta-thalassemia and myelodysplastic syndromes (MDS) in the BELIEVE and MEDALIST studies, respectivel

With only early-stage data in hand, The Medicines Co. ’s (MDCO) PCSK9 candidate, the centerpiece of its budding lipid franchise, is far behind competitors . But MDCO is counting on a highly differ

In Vitro Diagnostics Alliances

by Eric Eggers The PFO (patent foramen ovale) closure market has continued to mature in 2009, with the latest round of developments reported at the 2009 Transcatheter Cardiovascular Therapeutics (TCT)